Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00140
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
M1
|
|||||
| Sequence |
TFYGGRPKRNNFLRGIR
|
|||||
| Peptide Type |
Linear
|
|||||
| PDC Transmembrane Types | Cell-penetrating peptides (CPPs) | |||||
The Activity Data of This Peptide
| Peptide Activity Information 1 | [1] | |||||
| KD | 11.6 nM | |||||
|---|---|---|---|---|---|---|
| Binding Affinity Assay |
We therefore measured the binding kinetics of the peptide to LRP1 in the format of protein fusion.
|
|||||
| Experimental Condition | Low-density LRP1 | |||||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
M1-PTX [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Glioma | ||||
| Efficacy Data | Percent survival |
0%
|
|||
| Administration Time | 25 days | ||||
| Administration Dosage | Normalized to 17.3 mg/kg PTX | ||||
| Description |
The survival of the PTX group was markedly lower than that of the Vehicle group. M1-PTX did not improve survival, whereas the survival of the M1-RGD-PTX group was increased.
|
||||
| In Vivo Model | U87MG-Luc-bearing xenograft model. | ||||
| In Vitro Model | Glioblastoma | U87MG-Luc cell | CVCL_5J15 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Glioma | ||||
| Efficacy Data | Cell viability |
60%
|
|||
| Administration Time | 24 h | ||||
| Administration Dosage | 100 nM | ||||
| Evaluation Method | MTS assay | ||||
| Description |
Both PDCs showed higher in vitro cytotoxicity than free PTX.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cell | CVCL_0022 | ||
References